HomeCompareTRFE vs JNJ

TRFE vs JNJ: Dividend Comparison 2026

TRFE yields 547.47% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRFE wins by $124680.72M in total portfolio value
10 years
TRFE
TRFE
● Live price
547.47%
Share price
$0.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$124680.74M
Annual income
$91,722,882,389.26
Full TRFE calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — TRFE vs JNJ

📍 TRFE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRFEJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRFE + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRFE pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRFE
Annual income on $10K today (after 15% tax)
$46,534.55/yr
After 10yr DRIP, annual income (after tax)
$77,964,450,030.87/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, TRFE beats the other by $77,964,449,327.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRFE + JNJ for your $10,000?

TRFE: 50%JNJ: 50%
100% JNJ50/50100% TRFE
Portfolio after 10yr
$62340.38M
Annual income
$45,861,441,608.52/yr
Blended yield
73.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TRFE
No analyst data
Altman Z
38.6
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRFE buys
0
JNJ buys
0
No recent congressional trades found for TRFE or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRFEJNJ
Forward yield547.47%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$124680.74M$20.0K
Annual income after 10y$91,722,882,389.26$827.78
Total dividends collected$121875.03M$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TRFE vs JNJ ($10,000, DRIP)

YearTRFE PortfolioTRFE Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$65,447$54,746.52$10,676$355.77+$54.8KTRFE
2$404,885$334,856.98$11,407$389.39+$393.5KTRFE
3$2,369,294$1,936,067.16$12,198$426.53+$2.36MTRFE
4$13,123,393$10,588,248.86$13,056$467.62+$13.11MTRFE
5$68,853,012$54,810,981.60$13,987$513.12+$68.84MTRFE
6$342,430,230$268,757,507.18$14,998$563.56+$342.42MTRFE
7$1,615,583,097$1,249,182,750.83$16,098$619.52+$1615.57MTRFE
8$7,236,743,316$5,508,069,401.68$17,295$681.69+$7236.73MTRFE
9$30,801,732,611$23,058,417,263.04$18,599$750.82+$30801.71MTRFE
10$124,680,736,283$91,722,882,389.26$20,022$827.78+$124680.72MTRFE

TRFE vs JNJ: Complete Analysis 2026

TRFEStock

Healthmed Services Ltd. provides communications technology to provide individuals, companies, and health-provider organizations with telephone and Web-based access to medical advice, information, and products and services. The company was founded in 2000 and is based in Temecula, California.

Full TRFE Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this TRFE vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRFE vs SCHDTRFE vs JEPITRFE vs OTRFE vs KOTRFE vs MAINTRFE vs ABBVTRFE vs MRKTRFE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.